{
    "clinical_study": {
        "@rank": "68940", 
        "arm_group": {
            "arm_group_label": "Exenatide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the feasibility of exenatide infusion for the\n      treatment of high blood sugars following acute brain injury."
        }, 
        "brief_title": "Intravenous Exenatide in Patients With Acute Brain Injury", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Subarachnoid Hemorrhage", 
            "Brain Injuries"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Subarachnoid Hemorrhage", 
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults \u226518 years\n\n          -  Moderate to severe neurologically brain injured patients with subarachnoid hemorrhage\n             (GCS \u226412) or severe traumatic brain injury (GCS <8) requiring and receives invasive\n             intracranial multi-modal monitoring\n\n          -  Blood glucose reading > 180 mg/dL and \u2264300 mg/dL within first 48 hours of hospital\n             admission\n\n          -  Informed consent obtained via proxy\n\n        Exclusion Criteria:\n\n          -  Pregnant (verified by urine or serum pregnancy test within 24 hours of initiation of\n             infusion) or lactating females\n\n          -  Type 1 diabetes mellitus\n\n          -  History of pancreatitis or risk factors for acute pancreatitis (i.e ethanol abuse,\n             gall stones)\n\n          -  Renal insufficiency defined as creatinine clearance (CrCL) < 45 mL/min\n\n          -  Known history of gastroparesis\n\n          -  History of surgery on stomach, esophagus or duodenum\n\n          -  Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic Nonketotic Syndrome\n\n          -  Concurrent steroid use or planned post-operative steroid use\n\n          -  History of organ transplantation\n\n          -  Brain death or suspected imminent brain death within the next 72 hours\n\n          -  Refractory intracranial hypertension defined as intracranial pressure (ICP) > 25 mmHg\n             for greater than 15 minutes and refractory to medical intervention\n\n          -  Currently enrolled in another investigational drug or device protocol\n\n          -  Insulin infusion within 3 hours of study drug administration or confirmed long acting\n             insulin or sulfonylurea use prior to admission within 24 hours of study drug\n             administration\n\n          -  Known allergy to exenatide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058940", 
            "org_study_id": "13-1391", 
            "secondary_id": "Bristol-Myers Squibb Company"
        }, 
        "intervention": {
            "arm_group_label": "Exenatide", 
            "description": "50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours", 
            "intervention_name": "Exenatide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "contact": {
                "email": "nickipinelli@unc.edu", 
                "last_name": "Nicole R. Pinelli, PharmD", 
                "phone": "919-962-1641"
            }, 
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599"
                }, 
                "name": "University of North Carolina; UNC Medical Center"
            }, 
            "investigator": {
                "last_name": "Nicole R. Pinelli, PharmD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intravenous Exenatide Infusion in Critically Ill Neurologic Injured Patients: A Proof of Concept Study", 
        "overall_contact": {
            "email": "nickipinelli@unc.edu", 
            "last_name": "Nicole R. Pinelli, PharmD", 
            "phone": "919-962-1641"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina, Chapel Hill", 
            "last_name": "Nicole R. Pinelli, PharmD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Feasibility defined as the proportion of patients 1) experiencing severe hypoglycemia (<40 mg/dL); 2) achieving glucose measurements within goal (110-180 mg/dL); and 3) experiencing nausea requiring discontinuation of exenatide therapy", 
            "safety_issue": "Yes", 
            "time_frame": "Over 48 hours from infusion initiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058940"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours", 
                "measure": "Mean glucose concentration during exenatide infusion", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours", 
                "measure": "Number of glucose measurements within goal (110-180 mg/dL)/total number of glucose measurements", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours", 
                "measure": "Mean time to reach glucose measurements within goal (110-180 mg/dL)", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours", 
                "measure": "Glycemic variability defined as the standard deviation of glucose", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from number of insulin units administered over 48 hours starting at infusion initiation", 
                "measure": "Mean insulin use (units/kg body weight)", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "measure": "Proportion of subjects requiring rescue insulin infusion protocol", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours", 
                "measure": "Number of hypoglycemic episodes (<80 mg/dL)/total number of glucose measurements", 
                "safety_issue": "Yes", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours", 
                "measure": "Number of subjects with >1 episode of hypoglycemia (<80 mg/dL)/total number of subjects", 
                "safety_issue": "Yes", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly microdialysis samples starting at infusion initiation over 48 hours", 
                "measure": "Proportion of patients experiencing metabolic crisis defined as cerebral microdialysate glucose concentration <0.7 mmol/L in combination with lactate pyruvate ratio >40", 
                "safety_issue": "Yes", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly measurements starting at infusion initiation over 48 hours", 
                "measure": "Mean daily intracranial and cerebral perfusion pressures", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "Calculated from hourly measurements starting at infusion initiation over 48 hours", 
                "measure": "Number of hypotensive episodes (SBP<100 mmHg)/total number of blood pressure measurements", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours from infusion initiation"
            }, 
            {
                "description": "death, life-threatening event, prolonged hospitalization, disability or incapacity, congenital anomaly or birth defect, or important non-life threatening medical event", 
                "measure": "Proportion of patients experiencing serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "source": "University of North Carolina, Chapel Hill", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of North Carolina, Chapel Hill", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}